Abstract
2357P TRX-221, a 4th generation, mutant-selective, and CNS-active EGFR inhibitor with robust antitumor activity in osimertinib-resistant tumor models harboring C797S mutation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have